Clinical Application of Tissue Plasminogen Activator Therapy in Acute Myocardial Infarction
Acute myocardial infarction is related to plaque rupture and thrombosis formation in the infarct-related coronary artery. Salvage of ischemic area with thrombolysis in the early stage of infarction has proved to be the best way to limit infarct size, preserve left ventricular function and reduce mortality in the majority of victims. Tissue plasminogen activator (tPA) is the most promising thrombolytic agent used to salvage ischemic myocardium; the efficacy has been systematically demonstrated in previous studies (1–4).
KeywordsAcute Myocardial Infarction Thrombolytic Therapy Patency Rate Activate Partial Thromboplastin Time Coronary Arteriography
Unable to display preview. Download preview PDF.
- 2.B. Sobel, Early intervention in acute myocardial infarction: One center’s perspective, Am. J. Cardiol., 69:983–990 (1984).Google Scholar
- 9.J. H. Chesebro, G. Knatterud, and R. Roberts, et al., Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase, clinical findings through hospital discharge, Circulation, 76:142–154 (1987).PubMedCrossRefGoogle Scholar
- 10.A. K. Rao, C. Pratt, and A. Berke, et al., Thrombolysis in myocardial infarction (TIMI) trial- Phase I: Hemorrhagic manifestation and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase, J. Am. Coll. Cardiol., 11:1–11 (1988).PubMedCrossRefGoogle Scholar